| DC49065 |
ERK1/2 inhibitor 3 |
ERK1/2 inhibitor 3 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 3 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2021218912A1, compound 1). |
|
| DC49067 |
ERK1/2 inhibitor 5 |
ERK1/2 inhibitor 5 is a potent inhibitor of ERK1/2. Mitogen-activated protein kinase (MAPK) plays an extremely important role in the signal transduction pathway, and extracellular signal regulated kinase (ERK) is a member of the MAPK family. ERK1/2 inhibitor 5 has the potential for the research or prevention of cancer, inflammation or other proliferative diseases (extracted from patent WO2020238776A1). |
|
| DC49086 |
KRAS G12C inhibitor 27 |
KRAS G12C inhibitor 27 is a KRAS G12C inhibitor with antitumor effects (WO2021109737). |
|
| DC49087 |
KRAS G12C inhibitor 26 |
KRAS G12C inhibitor 26 is a KRAS G12C inhibitor with antitumor effects (WO2021109737). |
|
| DC49108 |
HPK1-IN-9 |
HPK1-IN-9 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-9 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 112) . |
|
| DC49126 |
HPK1-IN-10 |
HPK1-IN-10 is potent inhibitor of HPK1. HPK1 is a serine/threonine protein kinase cloned from hematopoietic progenitor cells and belongs to the MAP4K family of mammalian Ste-20-related protein kinases. HPK1-IN-10 has the potential for the research of HPK1 related diseases (extracted from patent WO2021213317A1, compound 103) . |
|
| DC49132 |
KRAS G12C inhibitor 23 |
KRAS G12C inhibitor 23 is a KRAS G12C inhibitor. KRAS G12C inhibitor 23 inhibits H358 cells with an IC50 of 491 nM (WO2021218939A1, compound 1). |
|
| DC49137 |
KRAS G12C inhibitor 25 |
KRAS G12C inhibitor 25 is a KRAS G12C inhibitor. KRAS G12C inhibitor 25 inhibits SOSl-assisted GDP/GTP exchanging activity of KRAS-G12C mutant (IC50=0.48 nM). From WO2021216770A1 compound 3. |
|
| DC49138 |
KRAS G12C inhibitor 22 |
KRAS G12C inhibitor 22 is a KRAS G12C inhibitor extracted from patent WO2021219072A1, example 120. |
|
| DC49148 |
KRAS G12C inhibitor 28 |
KRAS G12C inhibitor 28 is a KRAS G12C inhibitor with an IC50 of 57 nM. KRAS G12C inhibitor 28 has antitumor effects (WO2021113595A1; Example 1). |
|
| DC49149 |
KRAS G12C inhibitor 20 |
KRAS G12C inhibitor 20 is a KRAS G12C inhibitor extracted from patent CN112694475A, example 1. |
|
| DC49155 |
KRAS G12C inhibitor 21 |
KRAS G12C inhibitor 21 is a KRAS G12C inhibitor extracted from patent WO2021219090A1, example 7. |
|
| DC50080 |
KRAS G12C inhibitor 29 |
KRAS G12C inhibitor 29 is a KRAS G12C inhibitor extracted from patent WO2021252339A1, compound 3. KRAS G12C inhibitor 29 can be used for the research of cancer. |
|
| DC50081 |
KRAS inhibitor-11 |
KRAS inhibitor-11 (compound 12) is a KRAS inhibitor. |
|
| DC50082 |
K20 |
K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 µM. K20 shows anticancer activity in H358 cells (IC50= 0.78 µM). K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity. |
|
| DC50083 |
KRAS G12D inhibitor 14 |
KRAS G12D inhibitor 14 is a potent KRAS G12D inhibitor with a KD of 33 nM for binding to KRAS G12D protein. KRAS G12D inhibitor 14 decreases the active form of KRAS G12D (KRAS G12D-GTP) but not KRAS G13D. |
|
| DC50254 |
PD-334581 |
PD-334581 is a MEK1 inhibitor. |
|
| DC70036 |
HPK1-IN-21 |
HPK1-IN-21 is a potent inhibitor of HPK1 kinase inhibitor (Ki=0.8 nM), HPK1-IN-21 also has orally active. |
|
| DC70037 |
RMM-46 |
RMM-46 is a selective and reversible covalent inhibitor for MSK/RSK-family kinases. |
|
| DC70038 |
RAF-IN-1 |
RAF-IN-1 is a potent b/cRAF inhibitor with an IC50s of 3.8 nM, 36 nM, 29.4 nM for cRAF, bRAFwt, and bRAFV600E. RAF-IN-1 shows cell growth inhibition with GI50s of 3.4 and 2.9 nM for H358 and A375 cell line bearing bRAFV600E mutation, respectively. |
|
| DC70039 |
SHR902275 |
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC50s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAFwt, and bRAFV600E, respectively. SHR902275 shows cell growth inhibition with GI50s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively. |
|
| DC70040 |
SOS1-IN-9 |
SOS1-IN-9 is a potent SOS1 inhibitor with an IC50 of 116.5 nM for SOS1-KRAS G12C (WO2022028506A1, compound 302). |
|
| DC70041 |
SOS1-IN-10 |
SOS1-IN-10 is a potent SOS1 inhibitor with an IC50 of 13 nM for KRAS G12C-SOS1 (WO2022017519A1, compound 8). |
|
| DC70042 |
KRAS G12C inhibitor 32 |
KRAS G12C inhibitor 32, an eight membered heterocyclic compound containing N, is a potent KRAS G12C inhibitor. |
|
| DC70043 |
ZINC09659342 |
ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction with an IC50 of 3.6 μΜ. |
|
| DC70044 |
KRAS G12C inhibitor 33 |
KRAS G12C inhibitor 33 is a KRAS G12C inhibitor extracted from patent WO2021244603A1, compound 1. KRAS G12C inhibitor 33 can be used for the research of cancer. |
|
| DC70045 |
SOS1-IN-11 |
SOS1-IN-11 is a potent SOS1 inhibitor with an IC50 value of 30 nM. |
|
| DC70046 |
MRTX 0902
Featured
|
MRTX0902 is a potent SOS1 inhibitor with an IC50 of 46 nM (WO2021127429A1; Example 12-10). |
|
| DC70047 |
KRAS G12C inhibitor 34 |
KRAS G12C inhibitor 34 is a KRAS G12C inhibitor extracted from patent WO2021239058A1, compound Z1. KRAS G12C inhibitor 34 can be used for the research of cancer. |
|
| DC70048 |
SOS1-IN-6 |
SOS1-IN-6 (compound 33-P1) is a potent SOS1 inhibitor with IC50s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively. |
|
